Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
Earnings Data
Report Date
Apr 01, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.Company Guidance
Expansion of TAMP Therapy
RenovoRx's TAMP therapy is gaining traction with academic medical centers, NCI-designated cancer centers, and large community hospitals. Early signs of clinical adoption are promising, with repeat use by physicians.
RenovoCath Commercial Momentum
Year-to-date revenue through Q3 was approximately $900,000. The company expanded from 5 to 14 leading cancer centers approved to purchase RenovoCath, with product quotes delivered to 10 additional centers, totaling 24 centers requesting quotes.
Strong Commercial Foundation and Financial Health
RenovoRx reported over $10 million in cash and cash equivalents, sufficient to fund ongoing commercial efforts and clinical trials into 2026. The company maintains fiscal discipline and is exploring multiple financing options to strengthen the balance sheet.
Clinical Trial Progress
The Phase III TIGER PACT trial continues with enrollment expected to complete in early 2026. The Data Monitoring Committee recommended continuing the study after the second interim analysis, indicating potential positive outcomes.
RNXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RNXT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $0.97 | $0.75 | -22.68% |
Aug 14, 2025 | $1.24 | $0.96 | -22.58% |
May 15, 2025 | $1.11 | $1.18 | +6.31% |
Apr 01, 2025 | $0.99 | $0.96 | -3.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RenovoRx (RNXT) report earnings?
RenovoRx (RNXT) is schdueled to report earning on Apr 01, 2026, After Close (Confirmed).
What is RenovoRx (RNXT) earnings time?
RenovoRx (RNXT) earnings time is at Apr 01, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNXT EPS forecast?
RNXT EPS forecast for the fiscal quarter 2025 (Q4) is -0.08.